Literature DB >> 25230815

The pharmacology and clinical application of thrombopoietin receptor agonists.

Caizheng Li1, Li Zheng.   

Abstract

The discovery and application of thrombopoietin (TPO) and thrombopoietin receptor (TPOR) agonists have changed the clinical treatment of thrombocytopenia. These compounds exert favorable clinical effects without the adverse events caused by traditional treatments (e.g., corticosteroids, immunoglobulins, monoclonal antibodies and splenectomy). This review provides a synopsis of new agents that boost platelet production, especially the TPOR agonists, and highlights their pharmacological characteristics and clinical applications.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25230815     DOI： 10.1007/s12185-014-1660-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  76 in total

Review 1.  Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura.

Authors:  Tingting Wang; Zhao Wang; Renchi Yang
Journal:  Crit Rev Oncol Hematol       Date:  2010-04-07       Impact factor: 6.312

Review 2.  Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.

Authors:  David J Kuter; C Glenn Begley
Journal:  Blood       Date:  2002-11-15       Impact factor: 22.113

Review 3.  Thrombopoietin: the novel hepatic hormone.

Authors:  Eva-Maria Wolber; Wolfgang Jelkmann
Journal:  News Physiol Sci       Date:  2002-02

4.  Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.

Authors:  Yukari Shirasugi; Kiyoshi Ando; Koji Miyazaki; Yoshiaki Tomiyama; Shinichiro Okamoto; Mineo Kurokawa; Keita Kirito; Yuji Yonemura; Shinichiro Mori; Kensuke Usuki; Koji Iwato; Satoshi Hashino; Helen Wei; Richard Lizambri
Journal:  Int J Hematol       Date:  2011-06-25       Impact factor: 2.490

Review 5.  The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production.

Authors:  Kenneth Kaushansky; Jonathan G Drachman
Journal:  Oncogene       Date:  2002-05-13       Impact factor: 9.867

6.  Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.

Authors:  Julian M Jenkins; Daphne Williams; Yanli Deng; Joanne Uhl; Valerie Kitchen; David Collins; Connie L Erickson-Miller
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

7.  Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets.

Authors:  Marcin Majka; Janina Ratajczak; Gaston Villaire; Krystyna Kubiczek; Leah A Marquez; Anna Janowska-Wieczorek; Mariusz Z Ratajczak
Journal:  Exp Hematol       Date:  2002-07       Impact factor: 3.084

8.  Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies.

Authors:  Louis M Aledort; Catherine P M Hayward; Mon-Gy Chen; Janet L Nichol; James Bussel
Journal:  Am J Hematol       Date:  2004-07       Impact factor: 10.047

Review 9.  Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.

Authors:  David J Kuter
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

Review 10.  Emerging treatments for thrombocytopenia: increasing platelet production.

Authors:  Karen Peeters; Jean-Marie Stassen; Désiré Collen; Chris Van Geet; Kathleen Freson
Journal:  Drug Discov Today       Date:  2008-07-17       Impact factor: 7.851
View more
  6 in total

1.  Identification of anti-thrombopoietin receptor antibody in prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation treated successfully with eltrombopag.

Authors:  Akihito Fujimi; Yusuke Kamihara; Akari Hashimoto; Yuji Kanisawa; Chisa Nakajima; Naotaka Hayasaka; Shota Yamada; Toshinori Okuda; Shinya Minami; Kaoru Ono; Satoshi Iyama; Junji Kato
Journal:  Int J Hematol       Date:  2015-05-13       Impact factor: 2.490

2.  H2S protects against fatal myelosuppression by promoting the generation of megakaryocytes/platelets.

Authors:  Huan-Di Liu; Ai-Jie Zhang; Jing-Jing Xu; Ying Chen; Yi-Chun Zhu
Journal:  J Hematol Oncol       Date:  2016-02-24       Impact factor: 17.388

3.  Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist.

Authors:  Chengying Xie; Huajun Zhao; Xubin Bao; Haoyu Fu; Liguang Lou
Journal:  J Cell Mol Med       Date:  2018-08-29       Impact factor: 5.310

4.  Efficacy and Safety of Avatrombopag in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Chunlu Li; Xiaoxuan Li; Feihong Huang; Jing Yang; Anguo Wu; Long Wang; Dalian Qin; Wenjun Zou; Jianming Wu
Journal:  Front Pharmacol       Date:  2019-07-26       Impact factor: 5.810

5.  Short- and long-term outcomes of 486 consecutive laparoscopic splenectomy in a single institution.

Authors:  Xiaowei Fu; Zhengjiang Yang; Shuju Tu; Wanpeng Xin; Haiming Chen; Xueming Li; Yong Li; Weidong Xiao
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

Review 6.  Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia.

Authors:  Angelica Maria Garzon; William Beau Mitchell
Journal:  Front Pediatr       Date:  2015-08-13       Impact factor: 3.418
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.